Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

hem-onc-updates

Advertisement

SPRYCEL® (Dasatinib)

November 17, 2017April 5, 2020 RR FDA Approvals
Chronic Myeloid Leukemia

The FDA on November 9, 2017, granted regular approval to SPRYCEL®, for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) in the Chronic Phase. SPRYCEL® is a product of Bristol-Myers Squibb Co.

Related Posts:

  • Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase…
  • Bosutinib as third-line therapy for chronic phase (CP)…

Post navigation

ADCETRIS® (Brentuximab vedotin)
GAZYVA® (Obinutuzumab)

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

OncoPrescribe-Ad

Advertisement

Ad 2

OncoPrescribe-CDC

Advertisement

Ad 3

OncoPrescribe-Ad

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved